Abnormal Weight Gain and Gut Microbiota Modifications Are Side Effects of Long-Term Doxycycline and Hydroxychloroquine Treatment (Publication with Expression of Concern. See vol. 66, 2022) (Retracted Article)
Abnormal Weight Gain and Gut Microbiota Modifications Are Side Effects of Long-Term Doxycycline and Hydroxychloroquine Treatment (Publication with Expression of Concern. See vol. 66, 2022) (Retracted Article)
复制标题
DOI：
10.1128/aac.02437-14
复制
发表时间：
2014-06-01
影响因子：
4.9
通讯作者：
Raoult, Didier
中科院分区：
文献类型：
--
作者：
Angelakis, Emmanouil;Million, Matthieu;Raoult, Didier
多西环素已被提议用于治疗发展中国家的营养不良儿童，其使用与健康志愿者的体重增加有关。以前没有研究评估异常体重增加作为长期多西环素治疗的假定副作用;因此，本研究的目的是表征这种现象。我们还分析了肠道微生物群在这种效应中的作用。我们评估了Q热心内膜炎患者用强力霉素和羟氯喹治疗后和健康人不用抗生素治疗后体重指数的变化。异常体重增加定义为体重增加超过对照组。使用分子测定法检查粪便样品中的史氏甲烷短杆菌、拟杆菌、厚壁菌、大肠杆菌、乳杆菌、罗伊氏乳杆菌和总细菌浓度。我们检查了82例患者，包括48例Q热心内膜炎患者和34例对照。约23%的治疗患者显示体重异常增加（P = 0.001）。用强力霉素和羟氯喹治疗的患者呈现出拟杆菌属（P = 0.002）、厚壁菌属（P = 0.01）和乳杆菌属（P = 0.02）的显著较低浓度。线性回归分析显示，治疗持续时间与拟杆菌门（P = 0.0001）、厚壁菌门（P = 0.002）和细菌总数（P < 0.00001）的减少显著相关。异常体重增加是长期强力霉素和羟氯喹治疗的副作用。在门水平上的肠道微生物群修饰可能在这种效应中发挥重要作用。我们强调需要对长期接受抗生素治疗的患者进行特殊的营养护理，特别是涉及使用强力霉素的治疗。
Doxycycline has been proposed for the treatment of malnourished children in developing countries, and its use has been associated with weight gain in healthy volunteers. No previous studies have assessed abnormal weight gain as a putative side effect of long-term doxycycline treatment; thus, the objective of the present study was to characterize this phenomenon. We also analyzed the role of the gut microbiota in this effect. We assessed changes in the body mass index in Q fever endocarditis patients treated with doxycycline and hydroxychloroquine and healthy individuals with no antibiotic treatment. Abnormal weight gain was defined as a gain in weight above that of the controls. The fecal samples were examined using molecular assays for Methanobrevibacter smithii, Bacteroidetes, Firmicutes, Escherichia coli, Lactobacillus, Lactobacillus reuteri, and total bacterial concentrations. We examined 82 patients, including 48 patients with Q fever endocarditis and 34 controls. Approximately 23% of the treated patients showed abnormal weight gain (P = 0.001). Patients treated with doxycycline and hydroxychloroquine presented significantly lower concentrations of Bacteroidetes (P = 0.002), Firmicutes (P = 0.01), and Lactobacillus (P = 0.02). The linear regression analysis revealed that the duration of treatment was significantly associated with a decrease in Bacteroidetes (P = 0.0001), Firmicutes (P = 0.002), and total bacteria (P < 0.00001). Abnormal weight gain is a side effect of long-term doxycycline and hydroxychloroquine treatment. Gut microbiota modifications at the phylum level could play an instrumental role in this effect. We highlight the need for specific nutritional care in patients undergoing long-term antibiotic treatment, particularly treatment involving the use of doxycycline.